Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer.

ABSTRACT:

Background

Despite benefits of endocrine therapy (ET) for patients with hormone-receptor (HR)-positive breast cancer, many patients do not initiate or discontinue ET against recommendations.

Methods

We identified variables associated with ET initiation and continuation, analyzing pooled data from two longitudinal studies at a National Cancer Institute comprehensive cancer center in St. Louis, Missouri. The sample included 533 women with newly diagnosed, non-metastatic, HR-positive breast cancer who completed interviews at enrollment and 6, 12, and 24 months after definitive surgical treatment. Logistic regression models estimated the adjusted odds ratio and 95% confidence interval (aOR [95% CI]) for each of self-reported ET initiation by the 12-month interview and continuati

SUBMITTER: Cho B 

PROVIDER: S-EPMC9341086 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature